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Breast cancer is the second most prevalent form of cancer in women worldwide, with
surgery remaining the standard treatment. The adverse impact of the surgery remains
controversial. It has been suggested that systemic factors during the postoperative period
may increase the risk of recurrence, specifically surgical site infection (SSI). The aim of
this review was to critically appraise current published literature regarding the influence
of SSIs, after primary breast cancer surgery, on breast cancer recurrence, and to delve into
potential links between these. This systematic review adopted two approaches: to identify
the incidence rates and risk factors related to SSI after primary breast cancer surgery; and,
secondly, to examine breast cancer recurrence following SSI occurrence. Ninety-nine
studies with 484,605 patients were eligible in the SSI-focused searches, and 53 studies
with 17,569 patients for recurrence-focused. There was a 13.07% mean incidence of SSI.
Six-hundred and thirty-eight Gram-positive and 442 Gram-negative isolates were identi-
fied, with methicillin-susceptible Staphylococcus aureus and Escherichia coli most com-
monly identified. There were 2077 cases of recurrence (11.8%), with 563 cases of local
recurrence, 1186 cases of distant and 25 cases which recurred both locally and distantly.
Five studies investigated the association between SSI and breast cancer recurrence with
three concluding that an association did exist. In conclusion, there is association between
SSI and adverse cancer outcomes, but the cellular link between them remains elusive.
Confounding factors of retrospective study design, surgery type and SSI definition make
results challenging to compare and interpret. A standardized prospective study with
appropriate statistical power is justified.
ª 2020 The Author(s). Published by Elsevier Ltd
on behalf of The Healthcare Infection Society. This is an open access article
under the CC BY license (http://creativecommons.org/licenses/by/4.0/).Medicine, University of
4703.
Dunne).
y Elsevier Ltd on behalf of T
mons.org/licenses/by/4.0/).Introduction
Predominantly a disease that presents in females, breast
cancer has been identified as the most commonly diagnosed
form of cancer in women globally, with an estimated 2 mil-
lion reported cases a year [1]. Breast cancer for the most part
is a treatable disease, with the survival rate improving due tohe Healthcare Infection Society. This is an open access article
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cancer recurrence remains a dominant contributor to breast-
cancer-related deaths. Specifically, this is when a sub-
population of primary tumour cells acquire genetic and epi-
genetic changes and may either persist as dormant or spread
systemically, evading treatment, and facilitating relapse
months or years later. When breast cancer recurs, the 5-year
survival rate can drop from 70e80% to less than 30% [3].
Breast cancer recurrence can occur as either local recurrence
(LR), at the same site, or as distant recurrence (DR), meta-
stasis to a different anatomical site, or both. The risk of 10-
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Figure 1. PRISMA flow diagram of search results focused on: (a) surgica
site infection and recurrence after primary breast cancer surgery.adjuvant therapy, but has been found to range from 4% to 34%
[4].
Surgery remains the standard treatment for breast cancer.
However, the adverse impact of surgery remains controversial,
although not yet fully understood. It has been suggested that
the change in tissue and tumour microenvironment (TME)
caused by the surgery may alter the growth kinetics of breast
cancer cells [5]. Surgical site infections (SSIs) have been shown
to be the leading cause of operation-related adverse events
[6,7]. They represent a significant issue that can reduce the
quality of life and prognosis of patients following surgery, as
well as increase the financial burden to patients, hospitals andrough PubMed
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cost of over $4000 per patient in the event of an SSI.
Breast surgery is classified as a clean surgical procedure,
with no exposure of the respiratory, alimentary or genito-
urinary tracts. As such, the expected rate of SSI incidence in
the postoperative period is approximately 1e3% [9]. However,
studies examining this have found that this approximation does
not hold up in practice, suggesting that such procedures should
be treated as clean-contaminated. Previous systematic liter-
ature reviews found that the use of antibiotic prophylaxis, not
normally required for clean surgeries, reduces the likelihood of
obtaining an SSI [10]. Indeed, breast cancer may be a key
variable associated with SSI. Infection rates are higher in
patients with breast cancer when compared with non-cancer
patients who undergo similarly extensive operations, such asbreast enhancement surgery [11]. Recent studies have also
demonstrated that the breast tumour microbiome is distinctly
different than that of the normal breast tissue, with a more
rich and diverse bacterial load. Interestingly, they also dem-
onstrated that breast tumours have larger and more diverse
microbiomes than any other tumours they examined [12].
The progression, treatment and prognosis of breast cancer is
influenced considerably by the TME. The TME in breast cancer
is a complex structure comprising of stromal cells, including
fibroblasts, mesenchymal stromal cells, osteoblasts, adipo-
cytes and pericytes as well as non-stromal cells, such as the
extracellular matrix (ECM) and immune cells [13,14]. Dis-
turbances of the TME, such as SSI at the time of primary sur-
gery, have been correlated with breast cancer recurrence
[15,16], but the mechanisms mediating this phenomenon have
Table I
Demographic information summaries for the two search topics
included in this review
SSI Recurrence
Studies (N) 99 53
Participants (N) 484605 17569
Countries (N) 29 20
Years of publication 1992e2019 1996e2019
Period of data collection (years) 1980e2018 1989e2017
Age (years) 54.6 (7.3) 53 (7.1)
Follow-up (months) 17 (26) 51 (25)
SSI (%) 13.07 6.8
Recurrence (N) 338 2077
Main study type Retrospective Retrospective
Main surgery type Varied Varied
Table III
Breast cancer surgery types recorded in the studies
Type of surgery Participants (N)
Varied 287051
Mastectomy 175711
Breast conserving surgery 19600
Reconstruction 1796
Axillary dissection 447
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local immune-derived antietumour response. Bacterial infec-
tion may potentially stimulate the host’s natural killer cells and
macrophages, inducing a strong anti-tumour immune response
protecting against invading pathogens and transformed cells,
including cancer cells [17]. Conversely, it has been suggested
that, as acute infections stimulate local levels of cytokines,
growth factors, and proteinases, these may in turn alter the
TME to support tumorigenesis. Breast cancer cells, influenced
by their microenvironment, ‘hack’ the tumour promoting
cancer-associated fibroblasts and cytokines, increasing pro-
liferation, migration and invasion [18,19].
While there is emerging evidence that occurrence of SSI may
relate to breast cancer recurrence, the influence that these
bacterial infections have on breast cancer recurrence rates and
the mechanisms required to enable cancer cells to reoccur in
the presence of infection, have yet to be determined. Con-
sequently, a more comprehensive understanding of SSIs and
their causative pathogenic microbes is critical to under-
standing their potential influence on the TME.
Therefore, the aim of this review was to critically appraise
current research regarding the role that SSIs and post-primary
breast cancer surgery play in wound healing and breast cancer
recurrence, and the plausible mechanisms associated with such
interaction.
This was performed using two approaches: the first objec-
tive was to explore SSIs after primary breast cancer surgery andTable II
Study designs reported in papers included in the review









Retrospective 53 331,379 39 9931
Prospective 26 147,067 7 706
Crossover/
controlled trials
11 2556 6 6803
Phase 2 trial 3 375 1 129
Case control 4 3226 e e
Case study 2 2 e e
Total 99 484605 53 17569the second aim was to examine cases of breast cancer recur-
rence following primary breast cancer surgery, where occur-
rence of SSIs were also recorded, and to delve into potential
links between these two events.
Methods
Search strategy
This review protocol was designed according to PRISMA
guidelines [20]. The electronic databases Web of Science
(1990e2020), PubMed (1950e2020), CINAHL (1961e2020), Sci-
ence Direct (1997e2020), Embase (1947e2020), Cochrane
(1993e2020) and Medline (1879e2020) were searched up to
March 2020, using the terms listed below, combined with
Boolean operators, in the title or abstract.
The first group of searches focused on SSIs after primary
breast cancer surgery using the keywords “Breast” “Infection”
“SSI” “surg*” “Cancer” or “tumor” or “tumour” “microbiol*“.
For example: (“Breast” AND (“Infection” OR “Surgical Site
Infection” OR “SSI”) AND (“Cancer” OR “Tumor” OR “Tumour”)
AND “Microbiology):ab,ti.
The second group of searches focused on breast cancer
recurrence following primary breast cancer surgery, where
occurrence of SSIs was also recorded, using the keywords
“Breast” “Cancer” or “Tumor” or “Tumour” “Infection” “SSI”
“Surgery” “Recurrence”. For example: (“Breast” AND (“Infec-
tion” OR “Surgical Site Infection” OR “SSI”) AND (“Cancer” OR
“Tumor” OR “Tumour”) AND “Recurrence”):ab,ti.
Inclusion criteria
Searches were limited to articles published in the English
language in a peer-reviewed journal only, with no specific year
limit. Articles found using the search terms, combined with
Boolean phrases, were assessed for eligibility. All articles were
imported to EndNote reference manager (Endnote X8) and
screened firstly based on title/abstract, and, if potentially
eligible, a more in-depth analysis of full text. Articles were
excluded if they were not available in English; if the patients
had not undergone primary breast cancer surgery; if they did
not involve breast cancer patients; if there was no mention of
infection or wound healing; and/or if they were protocol
papers or conference abstracts.
Data extraction
The study characteristics were extracted into Microsoft
Excel. These included study details, such as: location and type
































































































Figure 2. (a) Mean incidence of surgical site infection (SSI) in the 99 papers included in the SSI section of this study, including comparison
of rates according to length of follow-up period. Error bars represent standard deviation. (b). Characterization of bacteria isolated from
breast surgical wounds following breast cancer surgery. (c) Bacterial species identified from breast surgical wounds following breast
cancer surgery.
Table IV
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where they developed, causative pathogens and what defi-
nition was used to classify the infections. Secondary outcomes
were also recorded: number of postoperative complications,
cancer recurrence, smoking status and body mass index (BMI).
Graphs and figures were created using GraphPad Prism 8
(GraphPad Software, Inc.).Definitions used to classify whether a surgical site infection (SSI)
occurred in the included studies
Definition of SSI SSI Recurrence
N Per cent (%) N Per cent (%)
Not defined 45 45 49 92
Own criteria 18 18 2 4
CDC 24 24 1 2
NSQIP 1 1 1 2
Asepsis score 1 1 e e
Culture positive 10 10 e e
CDC, Centres for Disease Control and preventions; NSQIP, National
Surgical Quality Improvement Program.Results
Literature search
Following examination of full texts and application of
appropriate exclusion based on the aforementioned criteria,
searches that focused on SSI characteristics following primary
breast cancer surgery yielded 899 studies, of which 99 [21e60]
[61e100] [101e119] were eventually included in this arm of the
review. For the cancer recurrence focused search, 554 papers
were screened and 44 [15,16,23,59,78,82,93,104],[22,33,95,120e152] were included in the data extraction, as
depicted in Figure 1. The screen also identified two systematic
reviews [153,154] from which nine papers were found to be
eligible for inclusion [155e163]. In total, for the SSI arm, data
Table V
Association between infection and breast cancer recurrence












Abdullah et al., 2019
[23]
Ireland Retrospective 107 8 (7.5%) 19 (17.8%) 1 47 
Beecher et al., 2016
[15]
Ireland Retrospective 229 44 (19.2%) 44 (19.2%) 24 80 
Indelicato et al.,
2007 [59]
USA Retrospective 516 31 (6%) 46 (8.9%) 4 76.8 
Murthy et al., 2007
[16]
Israel Retrospective 1065 172 (16.2%) 93 (8.7%) 32 54 
Mousa et al., 2018
[147]
UK Retrospective 227 25 (11%) 30 (13.2%) e 37.4 
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29 countries with 127 different outcomes recorded. Data from
17,569 patients were extracted from across 20 countries with
56 different outcomes recorded in the recurrence arm, as
summarized in Table I. All patients were breast cancer patients
analysed following their primary cancer surgery.Type of study
Over 50% of the studies in the SSI arm of this review and over
65% of the recurrence studies used a retrospective study
design, as demonstrated in Table II. This involves screening and
extracting data from hospital charts of patients who had
undergone breast cancer surgery previously.Characterization of included surgery types
The majority of the studies did not classify their results
according to surgery type, pooling all breast cancer surgeries
together (Table III). Of those that did so, mastectomy was the
most common. These were further classified into total mas-
tectomy (N ¼ 111,931), partial mastectomy (N ¼ 52 723),
mastectomy followed by either immediate (N ¼ 6178) or
delayed reconstruction (N ¼ 4279) and modified radical mas-
tectomy (N ¼ 459). The category of surgery is an important
aspect when considering SSI, as there are multiple operative
factors such as surgical technique, surgery duration, disruption
to lymphatic drainage and neoadjuvant therapy that may
influence the likelihood of an infection.Table VI
Association between infection and breast cancer recurrence
Study Sample Recurrence N (%) Type of rec
Abdullah et al., 2019 [23] 107 8 (7.5%) 3 Local
Beecher et al., 2016 [15] 229 49 (21.4%) 6 Local
Indelicato et al., 2007 [59] 516 31 (6%) 31 Local
Murthy et al., 2007 [16] 1065 172 (16.2%) 17 Local
Mousa et al., 2018 [147] 227 25 (11%) 7 Local
IBR, immediate breast reconstruction; SSI, surgical site infection.SSI
A total of 14,455 cases of SSI were recorded from the
484,605 patients included in the SSI focused segment of this
review (2.98%). This ranged from 0.2% to 84.6%, with a mean
incidence of 13.07% (Figure 2a). Seventeen
[31,41,43,44,53,55,72,76,86e88,91,110e113,117] papers
recorded the culture results of the SSIs. Identification of the
causative bacterial species determined involvement of 638
Gram-positive and 442 Gram-negative isolates, as depicted in
Figure 2b. The most common causative bacteria identified
were meticillin-susceptible Staphylococcus aureus (MSSA),
responsible for 26% of the SSIs, Escherichia coli found in 20%,
followed by unspecified S. aureus strains (19%), Pseudomonas
aeruginosa (9%), meticillin-resistant S. aureus (MRSA) (6%),
Enterobacter cloacae (4%) and S. epidermis (4%), as illustrated
in Figure 2c.Definition of SSI
There was considerable variation in criteria employed to
define what represented an SSI throughout the studies included
in this review. The majority of the studies did not define the
criteria used to classify SSIs (Table IV). Nearly a quarter of the
studies in the SSI section and 2% in the recurrence searches
used the Centres for Disease Control and preventions (CDC)
guidelines. Eighteen percent used their own criteria and only
10% used a culture-positive result to establish SSI occurrence.
This is a result of the retrospective nature of the studies.urrence Type of surgery SSI definition
5 Distant 0 Both Mastectomy þ IBR Infection
30 Distant 8 Both Mastectomy þ IBR Would complication
0 Distant 0 Both Lumpectomy Infection
151 Distant 4 Both Varied Would complication
13 Distant 5 Both Mastectomy þ IBR Infection
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Follow-up was considered as the length of time the patients
were monitored for surgical complications, cancer recurrence
or any adverse events after surgery. Seventy-four of the 99
papers from the SSI search recorded how long patients were
followed for. The average follow-up was 17 months (27.8
months), ranging from 2 weeks to 144 months. Nearly 30% of
the studies (22) had a follow-up of one month. When comparing
length of follow-up, the studies that followed the patients for
one month or less had a mean SSI rate of 11%, while the studies
that followed their patients for more than one month had a
mean incidence of 13.4%. Although this increase is not large, it
indicates that perhaps, if all the studies involved monitored
their patients for an extended period of time, their incidence
of SSI may have increased.
The mean follow-up period for the recurrence studies was
51 months, ranging from three to 144 months. Even though they
had a longer follow-up period, they had a lower mean inci-
dence of SSI of only 6.6%. This is due to the focus and design of
the studies. Data were collected mostly on a retrospective
basis (Table I), and SSI was not the primary outcome of the
papers. Therefore, as a secondary outcome, there may have
been inconsistencies in their recording.
Cancer recurrence
Breast cancer recurrence was mentioned in only 15 of the 99
papers in the SSI alone searches
[22,23,32,45,59,61,64,70,78,79,82,93,95,104,105]; 8.6% of
these patients developed recurrence after surgery. Incidences
of recurrence and SSI were recorded independently of each
other in the studies, rather than linked and correlated. This
meant it was impossible to interpret the contribution SSI may
have made to these recurrences. There was also no classi-
fication of the recurrences into their local or distant subtypes.
This lack of clarity highlights the importance of the second
search of this study for a more in-depth analysis of recurrence
characteristics. Of the 17,569 patients in the recurrence-
focused section of this review, there were 2077 cases where
the breast cancer recurred (11.8%). The mean follow-up period
was 51 months, ranging from three months to 144 months.
There were 563 cases of LR, 1186 cases of DR, 25 recurred both
locally and distantly, and 303 cases did not specify whether
they were local or distant. The results are again limited by the
fact that 16 of the studies only recorded LR, suggesting that
perhaps there were more cases of DR that were not docu-
mented. This high rate of DR is especially worrisome as once
the cancer has progressed to this stage, full recovery is
unlikely.
Recurrence and SSI
Five studies (Tables V and VI) examined the association
between SSI and later cancer recurrence [16,23,59,147,164].
They were all retrospective reviews of hospital patient charts
and relatively small in size, with samples ranging from 107 to
1065 patients. They each recorded higher rates of infection
(8.7%e17.8%) than the suggested 1e3% for clean surgeries.
Four of the five papers stated whether or not the patients,
whose cancer had recurred, had experienced an SSI at time of
initial cancer surgery; 23.5% of the patients whose cancer hadrecurred had previously had an infection. Apart from Abdullah
[23], Cox regression analysis was used to check for association
between the initial SSI and subsequent hazard of developing a
recurrence. Three of the studies found an increased likelihood
of developing recurrence after acquiring an SSI [16,59,164] and
two found no association [23,147]. The three papers that
determined a positive association had longer postoperative
follow-up times and larger sample sizes than those that found
no association. Abdullah [23] only had one patient who expe-
rienced both recurrence and infection, and Mousa [147] did not
state how many patients experienced both. These studies were
limited by their small sample sizes and short follow-up periods.
It cannot be ruled out that, if a longer follow-up time was
employed and larger sample sizes, the studies would have
exhibited the same association as the other three studies.Other co-morbidities
The mean age of the breast cancer patients at time of sur-
gery from the SSI and recurrence searches were very similar,
54.6 (7.3) years and 53 (8.1) years, respectively. The par-
ticipants of this study had a mean BMI of 26.2 kg/m2 (2 kg/m2)
and thus were considered overweight. There was a record of
52,221 patients smoking or having previously been a smoker
before their primary breast cancer surgeries.Discussion
This review addressed two principal areas: first, establishing
the characteristics recorded regarding SSI after primary breast
cancer surgery; and second, examining the events of breast
cancer recurrence after SSI of the primary breast cancer sur-
gical wound and the plausibility that they are linked.
The first aspect of this review extracted data from 484,605
patients in the 99 eligible studies (Figure 1) and the second,
17,569 patients from 53 studies. The results of this review
suggest that the association between postoperative infection
and adverse cancer outcomes is clear, but the cellular link
between them remains elusive. There is evidence that specific
bacterial species are associated with SSI from the breast sur-
gical wound of the cancer patients. S. aureus, E. coli and
P. aeruginosa were the most common causative bacterial spe-
cies identified, consistent with emerging literature [165].
There was a high proportion of DRs. Five studies investigated
the association between SSI and breast cancer recurrence with
three concluding that an association did exist. Arising from this
review, albeit that confounding factors make results chal-
lenging to compare and interpret, there are sufficient data to
reasonably argue that a standardized prospective study with
appropriate statistical power is warranted.
The SSI incidence rates reported in individual studies are
quite variable, ranging from 0.2% to 48%. The majority of these
were higher than the 1e3% suggested SSI rate for clean sur-
geries of the breast [9]. There are no obvious explanations for
these inconsistencies in infection rates between institutions.
Previously, it had been suggested that staff training, the
experience of surgical and perioperative teams, and use of
antimicrobials prophylactically may all contribute to these
discrepancies [10,166]. Perhaps it proposes that the cancer
itself may be playing a role in the development of these
infections. This theory is supported by Olsen [11] who
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breast surgery and found that the cancer patients had a higher
incidence of SSI despite the fact that they have very similar
surgical procedures in terms of duration and invasiveness.
Interestingly, a recent study by Nejman [12] found that the
bacterial load of the tumour microbiome was much larger than
that of the normal breast samples, this was not the case for
other cancers, such as lung and ovarian.
There was considerable variation in criteria used to define
SSIs throughout the studies included in this review. Currently,
there is no worldwide ‘gold standard’ classification method,
making interpretation of the incidence rates challenging.
Table IV demonstrates how four different definitions of SSI
were used, but nearly 50% of studies did not mention whether
they employed a specific definition. Notably, a study per-
formed in the USA, found that by changing their definition of
what constituted an SSI after breast surgery, by excluding cases
of cellulitis, the incidence rate dropped from 8.7% to 2.7%
[167]. Moreover, the retrospective nature of the majority of
the studies may have influenced the SSI rate recorded, possibly
resulting in higher rates due to follow-up being conducted on
an outpatient basis. If an SSI developed but did not require
readmission then it may not have been documented in the
patient records, meaning it was not included in the study
[16,76]. Almost one-third of the studies had a follow-up period
of one month, owing to the fact that an SSI is typically defined
as occurring within the 30-day time period after surgery [168].
However, in the latest guidelines published by the Centres for
Disease Control and Prevention (CDC) they advise that a 90 day
surveillance period for surgeries of the breast should be
employed [169]. It is also worth noting that many of the papers
did, in fact, monitor the patients postoperatively for much
longer than the 30 day period suggested by the definition and,
consequently, recorded a higher incidence of SSI than those
only followed for one month. The mean rate of infection
increased from 11%, for those monitored for 30 days, to 13.4%
for those with a longer than 30 days follow-up period. However,
it should be noted that more standardization across studies is
needed in order to determine if this is a true difference. Other
studies have found that it may be necessary to extend the
surveillance to 265 days post-surgery in order to fully detect all
SSIs [170e172]. Overall, this inconsistency in the numerous SSI
definitions employed and capricious data-collection methods
acts as a confounder of results, making it challenging to com-
pare variables across studies.
The microbiome of breast tissue has normally been asso-
ciated with Gram-positive phyla such as staphylococci species
[173,174] but more recently it has been suggested that the
epidemiology of the breast, especially breast tumours, is
changing with more Gram-negative bacteria being identified in
surgical wounds [165]. The results of this review support this,
as it identified a much larger than expected volume of infec-
tions caused by Gram-negative bacilli, namely, E. coli and
P. aeruginosa (Figure 2). This may be suggestive of poor hygiene
and cleaning practices contaminating the surgical field or the
wound itself. The method of obtaining cultures was not
standardized; as such, some may have been obtained under
sterile conditions, and others may have been superficial swabs.
Methodological confounders may be reflected in studieswhereby, for instance, all of the 43 reported cases of E. cloacae
species were found by the Vilar-Compte group in Mexico
[110e112]. Similarly, Rolsten et al. from the USA are unique in
reporting Proteus mirabilis from the SSIs of the breast cancer
patients in their institution in Texas [87,88]. This is suggestive
of environmental factor or testing-related confounders that
contribute to the outcomes of their studies.
There was a lack of detail regarding cancer recurrences in
the papers included in the SSI portion of this review, possibly
due to their shorter follow-up period. In the recurrence-
focused section, there were 2077 cases of breast cancer
recurrence (11.8%). Five-hundred and sixty-three of the cases
were specified as LR, 1186 DR and 25 cases recurred in both
local and distant sites. The remainder did not specify whether
they were local or distant. Nearly half of the studies included in
this review did not differentiate their results based on the
different surgery types (Table III) making it difficult to compare
results across studies and infer results. Relatively recently, it
has been suggested that surgical trauma itself may influence
the TME, encouraging the harbouring of dormant cancer cells,
which may later circulate and initiate recurrence [175]. As well
as this potential dissemination of tumour cells, surgery results
in an increased immune response with increased release of
growth factors that may stimulate residual cancer cells, influ-
encing their behaviour and morphology, encouraging increased
proliferation, invasion, migration and resulting in DR [176].
Augmenting our understanding of how these interact and
influence this recurrence could prove vital in optimiszing pre-
cision medicine to reduce the likelihood of recurrence-
associated mortality.
The link between SSI and recurrence is underreported in the
literature, with only five papers found to examine their asso-
ciation. Three of the studies found an increased likelihood of
developing recurrence after acquiring an SSI [16,59,164] and
two found no association [23,147]. Although it should be noted
that the two studies that found no association employed shorter
follow-up times and smaller sample sizes. This interrelation
could be due to the fact that the immunogenic landscape of the
breast wound after surgery is associated with inflammation,
fever and release of cytokines and growth factors [177,178] and
that breast cancer itself displays immunogenic properties [18].
If an infection were to be added on top of this, the TME may
become further dysregulated. For example, endotoxin compo-
nents of bacteria infecting wounds have been shown to activate
the toll-like receptor pathway, triggering the intracellular sig-
nalling cascade to release pro-inflammatory cytokines [179].
SSIs also influence timing of adjunctive cancer therapies, such
as radiotherapy and chemotherapy, delaying them by up to six
weeks [180,181]. This increases the likelihood of cancer
recurrence, as these therapies are essential to quickly erad-
icating the residual cancer cells after the tumour is removed,
preventing their dissemination and regrowth. In breast cancer
specifically, delay to radiotherapy has been associated with
increased risk of recurrence and decreased overall survival
[182,183]. In this review, Murthy [16] and Beecher [164] dis-
played very similar findings, both reporting that the proba-
bilities of recurrence-free survival were reduced in patients
who had developed an SSI versus those who had not. Indelicato
[59] reported that each of their patients who failed local control
R.Í. O’Connor et al. / Journal of Hospital Infection 106 (2020) 522e535530after acute infection recurred locally, suggesting that perhaps it
is a process involved in delayed wound healing, such as a more
chronically inflamed TME, contributing to this increased risk.
While a link between SSI and later recurrence has been some-
what established, further study of the exact mechanisms
mediating this is warranted.
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